AbbVie gives Sosei a StaRring role in neurological drug discovery plans, paying $40M and committing $1.2B

AbbVie is tightening its ties to Sosei Heptares. Two years after forming an inflammatory and autoimmune pact, the Big Pharma is paying $40 million and committing up to $1.2 billion in milestones to expand its relationship with the specialist into neurological diseases.